Ready to start planning your care? Call us at 800-525-2225 to make an appointment.

×



Make an Appointment

Technologies Available for Licensing Treatment

Refer a Patient

ABOUT US

Our mission, vision & core values

Leadership

<u>History</u>

Equality, diversity & inclusion

Annual report

Give to MSK

RAF/MEK/MAPK pathway. This technology could be used for qualifying the cancer status and response in patients, for monitoring the efficacy of a chemotherapeutic regimen and for screening new compounds

Advantages

Excellent prognostic indicator in improving patient outcomes

Sensitive detection of anti-tumor response

Potential to tailor individual treatment regimen

Screening tool for new compounds

Novel therapeutic targets

Areas of Application

Therapeutic, prognostic, and research tool

Lead Inventors

Neal Rosen, MD, PhD, Laboratory Head, Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering

Patent Information

U.S. patent issued: 7,812,143

References

Presented at the AACR meeting (March 31st, 2006)

Pratilas CA, et al. (2008) Cancer Res; 68(22):9375-83

Pratilas CA, et al. (2009) Proc Natl Acad Sci U S A; 106(11):4519-24

Contact Information:

Lisa Kennedy, PhD

Senior Licensing Manager

Email: kennedl1@mskcc.org

Stage of Development

Animal studies

Indications

Indications > Cancer

Types

Diagnostics > Biomarkers

<u>Diagnostics</u> > <u>Molecular diagnostics</u>



Child & teen cancer types Integrative medicine Nutrition & cancer Find a doctor Research & Education Sloan Kettering Institute Gerstner Sloan Kettering Graduate School **Graduate medical education** MSK Library Communication preferences Cookie preferences Legal disclaimer Accessibility statement Privacy policy Price transparency **Public notices** © 2024 Memorial Sloan Kettering Cancer Center